Patent application number | Description | Published |
20090005292 | Novel Peptides that Bind to the Erythropoietin Receptor - The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided. | 01-01-2009 |
20090005325 | Ketolide Derivatives as Antibacterial Agents - Provided herein are ketolide derivatives, which can be used as antibacterial agents. Compounds described herein can be used for treating or preventing conditions caused by or contributed to by gram positive, gram negative or anaerobic bacteria, more particularly against, for example, | 01-01-2009 |
20090018174 | MACROLIDES AS ANTI-INFLAMMATORY AGENTS - Provided herein are macrolide derivatives that can be useful in treating or preventing inflammatory diseases. Also provided are pharmaceutical compositions comprising one or more macrolide derivatives optionally together with one or more pharmaceutically acceptable carriers, excipients, diluents or mixtures thereof, as well as methods for treating or preventing inflammatory diseases. | 01-15-2009 |
20090048147 | NITROGEN-BASED LINKERS FOR ATTACHING MODIFYING GROUPS TO POLYPEPTIDES AND OTHER MACROMOLECULES - The present invention relates to a compound comprising a peptide moiety, a linker moiety and a water-soluble polymer moiety such as a poly(ethylene glycol) moiety. The linker moiety is between the peptide moiety and the water-soluble polymer moiety. In certain embodiments, the linker moiety has the structure: | 02-19-2009 |
20090075916 | Use of Macrolide Derivatives for Treating Acne - This invention relates to 14-membered macrolide derivatives for treating or preventing acne vulgaris and associated inflammatory conditions. Also provided herein are medicaments or pharmaceutical compositions comprising one or more 14-membered macrolide derivatives together with one or more pharmaceutically acceptable carriers, excipients, diluents or mixture thereof, and methods for treating or preventing acne vulgaris and associated inflammatory conditions. | 03-19-2009 |
20090130225 | MACROLIDES DERIVATIVES AS ANTIBACTERIAL AGENTS - The present invention provides macrolide derivatives, which can be used as antibacterial agents. Compounds described herein can be used for treating or preventing conditions caused by or contributed to by gram-positive, gram-negative or anaerobic bacteria, more particularly against, for example, Staphylococci, Streptococci, Enterococci, | 05-21-2009 |
20110282029 | NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR - The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided. | 11-17-2011 |
20120157660 | NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR - The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided. | 06-21-2012 |
20120165275 | Nitrogen-Based Linkers for Attaching Modifying Groups to Polypeptides and Other Macromolecules - Compounds comprising a peptide moiety, a linker moiety and a water-soluble polymer moiety such as a poly(ethylene glycol) moiety are disclosed. Various linker moieties for use in these compounds are also disclosed, along methods for their synthesis. | 06-28-2012 |
20130012685 | NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR - The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided. | 01-10-2013 |